Acumen Pharmaceuticals Inc.

Last updated September 27, 2026
Favorite this organization

Organization details

Legal name
Acumen Pharmaceuticals Inc.
Ownership
Public
Status
Active
SIC code
2836 — Biological Products, (No Diagnostic Substances)
Jurisdiction of incorporation
Delaware
Headquarters city
Newton
Headquarters state / province
Massachusetts
Headquarters country
United States
Fiscal year end
December
Ticker symbol
ABOS
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001576885
EIN
36-4108129

Board of directors

Follow this board

Chief executives

Daniel Joseph OConnell · President and CEO
Dates unknown

Director election results

Annual meeting of June 3, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

8 of this board's directors also sit on 29 other boards.

Network of Acumen Pharmaceuticals Inc.'s board connections Artiva Biotherapeutics Inc. Artiva Biotherapeutics... Climb Bio Inc. Climb Bio Inc. LENZ Therapeutics Inc. LENZ Therapeutics Inc. ARS Pharmaceuticals Inc. ARS Pharmaceuticals In... Acrivon Therapeutics Inc. Acrivon Therapeutics I... Bicara Therapeutics Inc. Bicara Therapeutics In... Black Diamond Therapeutics Inc. Black Diamond Therapeu... Evommune Inc. Evommune Inc. Freenome Inc. Freenome Inc. Hemab Therapeutics Holdings Inc. Hemab Therapeutics Hol... Jade Biosciences Inc. Jade Biosciences Inc. Janux Therapeutics Inc. Janux Therapeutics Inc... Mineralys Therapeutics Inc. Mineralys Therapeutics... Nkarta Inc. Nkarta Inc. Parabilis Medicines Inc. Parabilis Medicines In... PepGen Inc. PepGen Inc. Kimberlee C. Drapkin Kimberlee C. Drapkin Laura Stoppel Laura Stoppel Peter Kolchinsky Peter Kolchinsky Rajeev M. Shah Rajeev M. Shah Acumen Pharmaceuticals Inc...
Shared director Other board Same sector +13 more in the list below

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$0
0 purchases by 0 insiders
Sold, last 12 months
$625,712
48 sales by 9 insiders
Date Insider Transaction Shares Price Value
Jun 17, 2026 Derrell Porter Director Option exercise +13,040 $1.07 $13,953
Jun 17, 2026 Derrell Porter Director Open-market sale −13,040 $2.33 $30,383
Jun 16, 2026 Derrell Porter Director Open-market sale −12,800 $2.33 $29,824
Jun 15, 2026 Derrell Porter Director Option exercise +6,460 $1.07 $6,912
Jun 15, 2026 Derrell Porter Director Open-market sale −6,460 $2.35 $15,181
Jun 9, 2026 Nathan B. Fountain Director Open-market sale −6,400 $2.23 $14,272
Jun 3, 2026 RA Capital Nexus Fund II, L.P. Director Grant or award +35,500 — —
Jun 3, 2026 Nathan B. Fountain Director Grant or award +35,500 — —
Jun 3, 2026 Kimberlee C. Drapkin Director Grant or award +35,500 — —
Jun 3, 2026 John A. Stalfort III Director Grant or award +35,500 — —
Jun 3, 2026 Derrell Porter Director Grant or award +35,500 — —
Jun 3, 2026 Jeffrey L. Ives Director Grant or award +35,500 — —
Jun 3, 2026 George Golumbeski Director Grant or award +35,500 — —
Jun 3, 2026 Laura Stoppel Director Grant or award +35,500 — —
Mar 16, 2026 Rajeev M. Shah Director, 10% owner Grant or award +6,060,606 $3.30 $20,000,000

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.